gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IRWDHealthcarePharmaceuticals

Ironwood Pharmaceuticals, Inc. - Class A (IRWD)

$3.77+7.71%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$3.77▲ 101.60% in range
Nov 4, 2025Low $1.87 · High $5.39Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Ironwood Pharmaceuticals, Inc. - closed at $3.77 on Nov 4, up 7.71%, 30.1% below its 52-week closing high. Volume of 2.6M shares was 1.58× its 20-day average (above normal).

Split-adjusted performance: +3.9% over one month, -21.9% over six months, +102.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $113.04M, up 32.6% from a year earlier, with a net margin of 45.4%.

Short interest was 15.9M shares at the Oct 15 settlement, up 2.1% from the prior report (10.6% of float, 8.0 days to cover).

Market cap$623.0M165.2M shares
Revenue · quarter$113.0M+32.6% YoY
Diluted EPS$0.31+121.4% YoY
P/E · TTM4.8×P/S 1.6×
Net margin45.4%Gross 100.0%
Dividend yieldNone
52-week range1.86 – 5.39−30.1% from high
Volume2.6M1.58× 20-day avg
Volatility · 60d49.5%Annualised
Short % of float10.6%8.0 days to cover
Net cash-$305.9MCash $79.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.4%1M +3.9%3M −11.5%6M −21.9%YTD +11.9%1Y +102.7%3Y −57.8%5Y −69.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum55
Revenue growth72
Net margin93
Value (low P/E)86
Size64

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short15.9M+2.1% vs prior
Days to cover8.0Settled Oct 15
% of float10.6%
Short vol. 10d52.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IRWDIronwood Pharmaceuticals, Inc. -$3.77+7.71%−21.9%+32.6%45.4%4.8$623.0M
APMDApnimed$15.30+1.59%————$637.0MCompare
NVCTNuvectis Pharma$18.47−4.50%+84.7%———$602.9MCompare
LXRXLexicon Pharmaceuticals$1.48+1.37%−7.5%−97.6%−4591.8%—$658.5MCompare
BCAXBicara Therapeutics$8.89−0.78%−62.6%———$588.3MCompare
OLMAOlema Pharmaceuticals$7.54+2.58%−50.4%———$659.7MCompare
IMMXImmix Biopharma$7.97+3.37%−22.8%———$660.7MCompare
ZVRAZevra Therapeutics$11.17+8.87%−0.7%+44.9%48.8%8.6$663.3MCompare
AVBPArriVent BioPharma$13.49+3.61%−54.5%———$665.2MCompare

News about Ironwood Pharmaceuticals, Inc. -

All news →
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?Zacks Investment Research · Oct 7, 2026▲ PositivePGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Zacks Investment Research · Sep 30, 2026▲ Positive

Quick answers

What does Ironwood Pharmaceuticals, Inc. - do?
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases.
What is IRWD's market cap?
$622.95M, based on the Nov 4 close of $3.77.
What is IRWD's P/E ratio?
4.8× trailing-twelve-month earnings of $129.87M.
Does Ironwood Pharmaceuticals, Inc. - pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IRWD is sold short?
15.9M shares, 10.6% of float, as of Oct 15, 2026.
What sector is IRWD in?
Healthcare, in the Pharmaceuticals industry.

About Ironwood Pharmaceuticals, Inc. -

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

HQ: Boston, MA100 employeesListed Feb 3, 2010ironwoodpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology